Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients
- PMID: 33831238
- DOI: 10.1111/apt.16323
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients
Comment in
-
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.Aliment Pharmacol Ther. 2021 May;53(9):1050. doi: 10.1111/apt.16340. Aliment Pharmacol Ther. 2021. PMID: 33831235 No abstract available.
Comment on
-
Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.Aliment Pharmacol Ther. 2021 Mar;53(5):616-629. doi: 10.1111/apt.16197. Epub 2021 Jan 19. Aliment Pharmacol Ther. 2021. PMID: 33464621 Clinical Trial.
References
REFERENCES
-
- Pol S, ANRS AFEF study group. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort. Aliment Pharmacol Ther. 2021;53:616-629.
-
- Teng YX, Li MJ, Xiang BD, Zhong JH. Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis. Gut. 2020;69:1900-1902.
-
- Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:246-258.e9.
-
- Iloeje UH, Yang H, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
-
- Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101:1797-1803.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical